PD-L1 ECD-Fc mRNA-LNP

PD-L1 (programmed cell death protein ligand 1), also known as CD274, is a type 1 transmembrane protein mainly expressed on the cell surface of tumor cells or antigen-presenting cells. PD-1, (also known as CD274), is a membrane protein of the human immunoglobulin superfamily, expressed on the surface of T cells, primary B cells, and myeloid-derived dendritic cells. PD-1 and PD-L1 were also found to be co-expressed on the surface of SCLC cancer cells. PD-1/PD-L1 act as inhibitory checkpoint molecules in the immune system. PD-1 binds to PD-L1 to form a complex and transmit inhibitory signals to reduce the proliferation and activity of killer T lymphocytes. Blocking PD-1 with anti-PD-1 antibody, or blocking PD-L1 with anti-PD-L1 antibody, can inhibit the formation of PD-1/PD-L1 complex, thereby activating the immune system to attack tumors. Therefore, both anti-PD-1 and anti-PD-L1 antibodies have been used as adjuvant therapy for certain types of cancer. This product is designed as a tool for the delivery and expression of PD-L1 ECD-mutant Fc mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of PD-L1 ECD-mutant Fc mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. This PD-L1 ECD mutant Fc fusion protein is a secreted protein, approximately 75 kD, consisting of the PD-L1 extracellular domain (ECD) and mutant Fc with a GS peptide linker (GGGGSGGGGSGGGGS) in between. The mutant Fc is approximately 50 kD with mutations L234A, L235A and P329G. The ECD of human PD-L1 is 220 amino acids, which is 19-238 amino acids of GenPept accession number: NP_054862. The full-length amino acid sequence of this PD-L1 ECD-mutant Fc product is available upon request.